This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1999 Feb 6;353(9151):499; author reply 500.

doi: 10.1016/S0140-6736(05)75172-2.

Interferon alfa for chronic hepatitis C infection

PMID: 9989746
DOI: 10.1016/S0140-6736(05)75172-2

Comment

Interferon alfa for chronic hepatitis C infection

D Kingsley. Lancet. 1999.

. 1999 Feb 6;353(9151):499; author reply 500.

doi: 10.1016/S0140-6736(05)75172-2.

Author

PMID: 9989746
DOI: 10.1016/S0140-6736(05)75172-2

No abstract available

PubMed Disclaimer

Comment on

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Poynard T, et al. Lancet. 1998 Oct 31;352(9138):1426-32. doi: 10.1016/s0140-6736(98)07124-4. Lancet. 1998. PMID: 9807989 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database